Pyrrolo-Dipyridine Compounds for Osteoblast-Driven Bone Formation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bone disorders, fractures, and related issues, such as osteoporosis and osteogenesis imperfecta, primarily focus on inhibiting bone resorption without effectively promoting bone formation, leading to insufficient bone density gains and fragility.
Innovation Solution
Development of pyrrolo-dipyridine compounds that modulate the Wnt/LRP and/or BMP signaling pathways to promote bone formation by stimulating osteoblast activity, either systemically or locally, and can be administered with osteoconductive agents or incorporated into medical devices for targeted bone growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antiresorptive therapies are used to stop bone resorption, then bone loss is reduced, but bone density gains are insufficient and bone formation is not effectively promoted
Solution Approach 1:
Instead of continuing to focus solely on inhibiting bone resorption (the conventional approach), the patent inverts the strategy by developing compounds that directly stimulate bone formation through osteoblast activation. The pyrrolo-dipyridine compounds shift the therapeutic focus from preventing bone loss to actively promoting bone buildup, thereby addressing the insufficient bone density gain problem.
Solution Approach 2:
The patent changes the therapeutic parameter from resorption inhibition to formation stimulation. By designing compounds that activate osteoblasts and promote mineral deposition, the therapy transitions from a protective mechanism (stopping loss) to a constructive mechanism (promoting gain), thereby improving bone density more effectively.
2Reliability
If existing antiresorptive treatments are administered, then bone resorption is inhibited, but bone formation stimulation remains inadequate
Solution Approach 1:
The patent inverts the conventional therapeutic approach by shifting from resorption inhibition to formation stimulation. The pyrrolo-dipyridine compounds directly target osteoblasts to enhance their mineral deposition activity, thereby strengthening bone formation capability rather than merely preventing bone loss.
Solution Approach 2:
The patent introduces pyrrolo-dipyridine compounds as intermediary agents that mediate between the therapeutic goal and the biological system. These compounds act as intermediaries that specifically activate osteoblasts and Wnt signaling pathways, thereby enhancing bone formation capability without directly interfering with resorption processes.
3Productivity
If bone formation is promoted through osteoblast stimulation, then bone density increases, but effective compounds with this mechanism are limited
Solution Approach 1:
The patent creates a universal therapeutic platform with pyrrolo-dipyridine compounds that can be applied across multiple bone-related conditions. The compounds' ability to stimulate osteoblasts and promote bone formation makes them versatile for treating osteoporosis, fracture healing, osteogenesis imperfecta, and other bone disorders, thereby enhancing therapy applicability.
Solution Approach 2:
The patent changes the chemical and biological parameters of available therapies by introducing a new class of compounds with distinct molecular structures (pyrrolo-dipyridine core) and mechanisms of action (osteoblast stimulation via Wnt pathway activation). This parameter change expands the range of effective treatments for bone formation promotion.
Data Source
AI summary
In one aspect, the invention provides compounds of Formula I Formula Ia, Formula Ib, Formula Ic, and Formula Id and salts, hydrates and isomers thereof. In another aspect, the invention provides a method of promoting bone formation in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of Formula I, Formula Ia, Formula Ib, Formula Ic, or Formula Id. The present invention also provides orthopedic and periodontal devices, as well as methods for the treatment of renal disease, diabetes bone loss, and cancer, using a compound of Formula I, Formula Ia, Formula Ib, Formula Ic, or Formula Id.